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Background: The clinical implication of Ras/Raf/ERK pathway activity in breast cancer tissue and its association with
response to chemotherapy is controversial. We aimed to explore the value of p90RSK phosphorylation, a
downstram molecule of the pathway, in predicting chemotherapy response in breast cancer.
Methods: The expression of phosphorylated p90RSK (phospho-p90RSK) and chemotherapy response was measured
in 11 breast cancer cell lines and 21 breast cancer tissues. The predictive value of phospho-p90RSK was validated in
core needle biopsy specimens of 112 locally advanced breast cancer patients who received anthracycline and
taxane-based neoadjuvant chemotherapy.
Results: In 11 breast cancer cell lines, the relative expression of phospho-p90RSK was inversely correlated with cell
survival after doxorubicin treatment (p = 0.021). Similar association was observed in fresh tissues from 21 breast
cancer patients in terms of clinical response. In paraffin-embedded, formalin-fixed tissues from core needle biopsy
tissues from 112 patients, positive phospho-p90RSK expression was associated with greater tumor shrinkage and
smaller post-chemotherapy tumor size. The association between phospho-p90RSK expression and chemotherapy
response was more evident in estrogen receptor(ER)-positive tumors. The expression of phosphor-p90RSK did not
show a significant relationship with the incidence of pCR. P90RSK silencing using siRNA did not affect the cancer
cell’s response to doxorubicin, and the expression of phospho-p90RSK was highly correlated with other Ras/Raf/ERK
pathway activation.
Conclusion: Our results suggest that phospho-p90RSK expression, which reflects the tumor’s Ras/Raf/ERK/p90RSK
pathway activation can be a potential predictive marker for chemotherapy response in ER-positive breast cancer
which needs further independent validation.
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Breast cancer is the most common solid cancer in women
worldwide. Recent improvement in breast cancer survival is
largely due to increased early detection and development of
effective systemic chemotherapeutic agents [1]. Currently, a
significant proportion of breast cancer patients received
adjuvant systemic chemotherapy since meta-analysis results* Correspondence: dynoh@snu.ac.kr
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reproduction in any medium, provided the orhave shown that adjuvant systemic chemotherapy is benefi-
cial regardless of the age and estrogen receptor (ER) expres-
sion [2]. Recent efforts are focused in developing molecular
markers which would identify a subset of patients in whom
the benefit of the cytotoxic chemotherapy is minimal and
can be omitted. Various multi-gene signatures were pro-
posed to predict the clinical benefit of chemotherapy in
breast cancer, however, only the 21-recurrence score
(Oncotype Dx) is currently approved for this purpose [3].
Ras/Raf/ERK signaling pathway has been shown to be
involved in intrinsic resistance to endocrine therapy in
breast cancer while its role in developing resistance totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[6] have previously shown that treatment with anthra-
cycline in various breast cancer cell lines resulted in
activation of ERK1/2 pathway and increased phospho-
rylation of its downstream molecule 90 kDa ribosomal
S6 kinase (p90RSK) in a time-dependent manner. Fur-
thermore, the mitogen-activated protein kinase (MAPK)
phosphatase which downregulate p90RSK can modulate
the chemotherapy-sensitivity in various cancer cell lines [7].
Recent studies have further suggested the importance of
p90RSK dysregulation in breast cancer development and
progression [8,9]. However, the clear role of this Ras/Raf/
ERK/p90RSK pathway in modulating chemotherapy
responsiveness is often difficult to estimate in ER-positive
breast cancer who receive both endocrine and cytotoxic
systemic therapies since the pathway clearly participate in
developing endocrine resistance [10].
In this study, we evaluated the predictive value of the
phosphorylated p90RSK expression in terms of chemothe-
rapy responsiveness in various breast cancer cell lines. The
clinical value of phospho-p90RSK was further tested in
locally advanced breast cancer patients who underwent
neoadjuvant systemic chemotherapy which is a valuable
platform to test the in vivo chemotherapy-sensitivity [11].
Methods
Patients and treatments
The Seoul National University Breast Care Center database
includes clinicopathologic informations of the breast cancer
patients treated at Seoul National University Hospital since
1990 [12]. From the database, we identified patients with
locally advanced breast cancer who underwent doxorubicin
and taxane-based neoadjuvant chemotherapy. For immu-
nohistochemistry against phospho-p90RSK, we were able
to identify 112 patients who had locally advanced breast
cancer, underwent doxorubicin and taxane-based neoadju-
vant chemotherapy between Jan 2010 and Dec 2011, did
not receive HER2-directed targeted therapies, and had
available pre-chemotherapy and post-chemotherapy
magnetic resonance imaging for response determi-
nation. For western blotting against phospho-p90RSK,
patients whose fresh frozen tissues were available were
selected from database. Tissues were obtained during
diagnostic ultrasonography-guided core needle biopsy pro-
cedures and stored at -80C. Informed consent was obtained
from all patients and the study was approved by the institu-
tional review board of Seoul National University Hospital.
All experiments and analyses were done in accordance with
the Declaration of Helsinki.
Our neoadjuvant chemotherapy regimens for locally
advanced breast cancer patients were previously described
[13]. Briefly, patients received docetaxel (75 mg/m2 or
60 mg/m2) and doxorubicin (60 mg/m2 or 50 mg/m2) via
intravenous infusion every three weeks with granulocytecolony stimulating factor as primary prophylaxis, or
doxorubicin (60 mg/m2 or 50 mg/m2) and cyclophos-
phamide (600 mg/m2) followed by docetaxel (75 mg/m2
or 60 mg/m2).
Cell culture and chemoetherapeutic agent
MCF10A, MCF7, MDA-MB-231, MDA-MB-436 and
MDA-MB-453 cell lines were obtained from the
American Type Culture Collection (ATCC), MDA-
MB-468, ZR75-1, BT474, Hs578T and T47D cell lines
were obtained from Korea Cell Bank (KCB). MCF10A
Cell line was grown in DMEM/F12 (Gibco) media with
5% horse serum (Invitrogen), 1% penicillin/streptomycin
(Gibco), 0.5 μg/ml hydrocortisone (Sigma), 100 ng/ml
cholera toxin (sigma), 10 μg/ml insulin (Sigma), and
20 ng/ml recombinant human EGF (Invitrogen). MDA-
MB-231, MDA-MB-436, MDA-MB-453, MDA-MB-468
and Hs578T cell lines were cultured in DMEM (Gibco)
with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin. All other cell lines were grown in RPMI
1640 with 10% FBS and 1% penicillin/streptomycin.
Doxorubicin was purchased from Sigma-Aldrich. The
expression status of ER and HER2 in various breast cancer
cell lines was determined by the works of Subik et al. [14]
and Neve et al. [15].
Sphere culture and cell growth
Spheres were generated from single cells of lines MCF7
and MDA-MB-231 seeded at 103 cells in 10 mm low
attachment plates (Falcon) and cultured in serum-free
DMEM (Dulbecco’s Modified Eagles Medium):F12 = 3:1
medium supplemented with 20 ng/mL epidermal growth
factor (EGF; Invitrogen), 20 ng/mL basic fibroblast growth
factor (bFGF; Millipore), 10 ng/mL leukemia inhibitory
factor (LIF, Millipore), B27 supplement (Invitrogen) and
antibiotic-antimycotic (Invitrogen). Cells were grown under
these conditions as nonadherent spherical clusters. The
medium was replenished every 3 ~ 4 days, and cells were
obtained after 1 week.
Cells were seeded and grown in the optical density of
cells in 100 mm culture dishes and 10 nM doxorubicin was
added 24 hours later. An equivalent volume of sterile water
(vehicle) was added as a control. At designated times
(72 hours) the cells were harvested, stained with trypan
blue (Invitrogen), and counted with a hemocytometer.
Three to five independent assays were performed for each
of the experiments.
Tissue protein extaction and western blot analysis
To extract total protein, all tissues were weighed and
placed in homogenization buffer at a ratio of 100 mg tissue
per 0.25 mL using total protein extraction kit (Chemicon
International), according to the manufacturer’s instructions.
The homogenates were rotated and centrifuged for
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supernatant and total protein concentration was deter-
mined with the Bradford assay using a Bio-Rad Protein
Assay kit (Bio-Rad Laboratories), according to the manu-
facturer’s instructions. Cells were washed twice with PBS,
and total cell lysates prepared in lysis buffer using total
protein extraction kit (Chemicon), equal amounts of cells
or tissue lysates were separated by SDS-PAGE gel.
The antibodies against total p90RSK (32D7), Phospho-
p90RSK (Thr359/Ser363), Phospho-Bad (Ser112, 40A9),
p44/42 MAPK (137 F5) and Phospho-p44/42 MAPK
(Thr202/Thr204, D13.14.4E) were purchased from Cell
Signaling Technology, whereas alpha-tubulin (B-7) and
BAD (C-7) were purchased from Santa Cruz Biotechnology.
Primary antibodies were detected using horseradish pe-
roxidase–linked anti-mouse anti-rabbit conjugates as ap-
propriate (DAKO), and visualized using the enhanced
chemiluminescence detection system (Amersham Bio-
sciences). Protein expression levels were quantified using
the software ImageJ to detect intensity of the protein bands.
Immunohistochemical staining
The paraffin-embedded formlin-fixed core needle biopsy
tissues from the above-mentioned 112 patients before the
initiation of neoadjuvant chemotherapy were collected for
phospho-p90RSK immunohistochemical staining. Serial
sections from formalin-fixed, paraffin-embedded (FFPE)
blocks were applied to 3-aminopropyltriethoxysilane-
coated slides. Deparaffinization and rehydration were per-
formed using xylene and alcohol. The slides were pre-
treated in a microwave oven for antigen retrieval. Sections
were incubated for 30 min at room temperature with anti-
bodies against phospho-p90RSK (1:50 dilution, Ab #9344,
Cell Signaling, MA). To block endogenous peroxidase
activity, treatment with blocking reagent (DAKO,
Glostrup, Denmark) for 5 min was carried out before in-
cubation with primary antibody for 30 min at 25°C.
Enzyme-conjugated polymer (DAKO) and diaminoben-
zidine (DAKO) were used as a visualization system and
chromogen, respectively. The phospho-p90RSK expres-
sion was measured by evaluating both intensity and area.
Most normal duct epithelial cells showed weak or strong
positive staining in variable% of cells. Stromal cells were
negative. Tumors showing weak nuclearcytoplasmic
staining of phospho-pRSK in more than 50% cells or
stronge nuclearcytoplasmic staining in more than 20%
of cells were considered to be positive for phospho-
p90RSK expression.
Definition of phenotype and response to neoadjuvant
chemotherapy
ER, PR, and HER2 expression patterns were evaluated with
the standard avidin–biotin complex immunohistochemical
staining method, as described previously [16]. The ER andPR results were interpreted as positive when more than
10% of tumor cells showed positive nuclear staining.
Tumors with indeterminate HER2 immunohistochemistry
results were further evaluated using FISH.
Magnetic resonance imaging is the most accurate
method of assessing the residual tumor extent in patients
who undergo neoadjuvant chemotherapy when compared
to mammography or ultrasonography [17]. Therefore, we
used the pre-chemotherapy and the post-chemotherapy
magnetic resonance imaging to determine the degree of
tumor response. Our protocol for breast cancer magnetic
resonance imaging was previously reported [17]. Pathologic
complete response (pCR) was defined as the absence of
residual invasive tumor cells at the primary tumor site as
defined by the NSABP [18].
Statistic analysis
The chi-square test and Student’s t test were used to
compare clinicopathologic variables between groups.
Mann–Whitney test was used to determine the difference
in phosphor-p90RKS expression between 10 chemo-
sensitive tumors and 10 chemo-resistant tumors measured
by western blotting. Pearson’s correlation analysis was used
to determine the relationship between phosphor-p90RSK
expression and other Raf/MEK/ERK pathway molecules.
All statistical analyses were performed using IBM SPSS
Statistic software version 19 (IBM, Armonk, New York).
Results
We screened phospho-p90RSK expression level and the
proportion of surviving cells after doxorubicin treatment in
various breast cancer cell lines (Figure 1a). Relative
phospho-p90RSK expression in these 12 breast cancer cells
were inversely associated with the sensitivity to doxorubicin
(Pearson correlation coefficient = −0.653, Figure 1b). The
absolute expression level of phosphor-p90RSK showed
similar association with the degree of response to doxoru-
bicin but with borderline statistical significance (p = 0.083,
Additional file 1: Figure S1). Then, we examined the
phospho-p90RSK expression in fresh frozen tissue samples
of 21 breast cancer before the initiation of neoadjuvant
chemotherapy. When the patients were classified according
to the RECIST criteria, patients who experienced clinical
response to neoadjuvant chemotherapy had tumors with
higher phospho-p90RSK expression (Mann–Whitney test
p = 0.024 for phosphor-p90RSK, p = 0.004 for phosphor-
p90RKS/total p90RSK, Figure 2a). Among the 21 patients,
pre-chemotherapy and post-chemotherapy magnetic reso-
nance imaging data (MRI) were available in 11 patients.
The degree MRI-measured radiologic tumor shrinkage was
higher in patients with high phospho-p90RSK expressing
tumors (Figure 2b).
We extended the clinical implication of phospho-p90RSK
expression in pre-chemotherapy core needle biopsy
Figure 1 The expression of phospho-p90RSK in various breast cancer cell lines and doxorubicin sensitivity. The levels of protein
expression of phospho-p90RSK and total p90RSK were examined in 11 breast cancer cell lines (a). The scattered plot for correlation analysis
between relative phospho-p90RSK expression and sensitivity to doxorubicin is shown (b). Cell survival* denotes for the proportion of cancer cells
surviving after doxorubicin 10uM treatment. The expression status of ER and HER2 in various breast cancer cell lines was determined by the
works of **Subik et al. [14] and ***Neve et al. [15].
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who underwent neoadjuvant chemotherapy with anthra-
cyclin and taxane-based regimens. We chose to measure
the expression level of phosphor-p90RSK expression by
immunohistochemistry since measuring the relative phos-
phorylation ratio seemed impractical considering the
semi-quantitative nature of the immunohistochemistry.
The representative figures of immunohistochemical stain-
ing are shown in Figure 3. Among the 112 patients, 77
patients (70.5%) showed positive phospho-p90RSK expres-
sion. The association between phospho-p90RSK expression
and various clinicopathologic tumor characteristics are
shown in Table 1. Positive phospho-p90RSK expressionwas associated with younger age at diagnosis (p = 0.004).
However, phospho-p90RSK did not show significant rela-
tionship with factors reported to affect the tumor response
to neoadjuvant chemotherapy such as initial clinical stage
or ER expression status [13]. Figure 4 shows the response
to neoadjuvant chemotherapy according to the phospho-
p90RSK expression. The pathologic extent of residual
breast cancer after neoadjuvant chemotherapy was smaller
in phospho-p90RSK positive tumors with borderline statis-
tical significance. Furthermore, phospho-p90RSK positive
tumors showed significant better response to neoadjuvant
chemotherapy in terms of radiologic residual tumor extent
and proportional tumor size reduction (Figure 4a and
Figure 2 The expression of phospho-p90RSK in human breast
cancer undergoing neoadjuvant chemotherapy. In 10 locally
breast cancer patients, phospho-p90RSK and total p90RSK expression
were measured by western blotting in core needle biopsy
specimens of breast cancer before initiation of neoadjuvant
chemotherapy. Patients were classified according to RECIST criteria
determined by the treating physician (a and b). In 11 patients in
whom the pre-chemotherapy and post-chemotherapy magnetic
resonance imaging were available, the expression of phospho-
p90RSK in tumor tissue and their corresponding radiologic tumor
volume shrinkage are shown in (b).
Table 1 Comparison of clinical and pathologic






Mean age 55.3 (±10.4) 48.3 (±11.9) 0.004
Initial tumor size
(cm)
5.1 (±2.3) 5.2 (2.4) 0.734
cT stage cT1-2 18 (55%) 38 (48%) 0.339
cT3-4 15 (45%) 41 (52%)
cN stage cN0-1 21 (64%) 40 (51%) 0.149
cN2-3 12 (36%) 39 (49%)
pCR pCR no 29 (88%) 72 (91%) 0.414
pCR yes 4 (12%) 7 (9%)
Estrogen receptor ER negative 18 (55%) 42 (53%) 0.530
ER positive 15 (45%) 37 (47%)
Progesterone
receptor
PR negative 10 (67%) 36 (64%) 0.560
PR positive 5 (33%) 20 (36%)
HER2 overexpression HER2
negative
10 (67%) 39 (70%) 0.527
HER2 positive 5 (33%) 17 (30%)
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pression was more evident in ER-positive tumors when
compared to ER-negative tumors. However, the phosphor-
p90RSK expression did not show a statistically significant
relationship with the incidence of pCR in both univariate
and multivariate analysis (Additional file 2: Table S1). Only
a borderline statistical significance was seen in multivariate
regression analysis.
We next evaluated the functional importance of p90RSK
in modulating chemotherapy response by silencing p90RSK
with siRNA. We chose 2 ER-expressing breast cancer cell
lines since the association between phosphor-p90RSK and
chemotherapy responsiveness was significant in ER-positivetumors. Unlike the hypothesis, p90RSK silencing did not
result result in decreased sensitivity to doxorubicin in
ZR-75-1 and MCF7 breast cancer cell lines (Figure 5a). The
expression of phospho-p90RSK was investigated in the con-
text of Raf/MEK/ERK/p90RSK pathway activation in 20
primary breast cancer patients. In breast cancer tissues, the
phospho-p90RSK expression was highly correlated with
phospho-c-Raf (p = 0.012), phospho-MEK (p = 0.003),
phospho-ERK (p = 0.009), and its downstream molecule
phospho-ELK (p = 0.079), suggesting that the expression of
phospho-p90RSK may reflect the whole Raf/MEK/ERK
pathway and thereby mediating chemotherapy response.Discussion
In this study, we show that the degree of phosphorylation
at p90RSK, a downstream molecule of ERK, is associated
with the response to doxorubicin and taxane-based chemo-
therapy in breast cancer. By examining 12 breast cancer cell
lines, we observed a significant relationship between the
degree of phospho-p90RSK expression and survival after
exposure to doxorubicin. Additionally, the expression of
phospho-p90RSK measured by western blotting and
immunohistochemistry in human breast cancer tissue
was associated with the response to neoadjuvant
chemotherapy in locally advanced breast cancer. Our
results suggest the potential usefulness of measuring
phospho-p90RSK as a predictive marker for response
before the neoadjuvant chemotherapy.
Figure 3 Immunohistochemical staining against phospho-p90RSK in human breast cancer tissue. Protein expression of phospho-p90RSK
in human breast cancer tissue was examined by immunohistochemistry. In upper panels, the representative immunohistochemical staining
images of phospho-p90RSK negative (a), weak (b), and strong (c) expression are shown (magnification X10). In lower panels, X20 magnified
images corresponding to the red-dashed square are shown.
Figure 4 Phospho-p90RSK expression and response to neoadjuvant chemotherapy. In 112 locally advanced breast cancer patients, the
expression of phospho-p90RSK expression and the radiologic tumor size shrinkage were examined. Pre-chemotherapy radiologic tumor size and
postchemotherapy tumor size (a), proportional tumor size reduction, and post-chemotherapy pathologic tumor size (b) were examined in all
tumors (left panel), estrogen receptor-positive tumors (middle panel), and estrogen receptor-negative tumors (right panel). * denotes for p < 0.05
from Student’s t-test.
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Figure 5 Results of p90RSK gene silencing in cancer cell lines and various Raf/Ras/ERK pathway activation in human breast cancer.
p90RSK inhibition was done in MCF7 and ZR-75-1 cells by using siRNA against p90RSK. Student t-test showed no significant difference in cell
proliferation in cells treated with siRNA against p90RSK and cells treated with scramble siRNA (a). The expression levels of total and
phosphorylated various Raf/Ras/ERK pathway molecules were measured in primary breast cancer tissues from 20 breast cancer patients.
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progression has recently been investigated in various types
of malignancies. p90RSK is required in mTORC1 activation
in BRAF-mutated melanoma cells which leads to increased
growth in vitro [19]. p90RSK is also involved in invado-
podia formation for cancer cell migration through the
extracellular matrix [20]. Furthermore, it has been recently
suggested that p90RSK is an important mediator of epithe-
lial mesenchymal transition and cancer cell migration [21].
Based on these recent observations, p90RSK is now consi-
dered to be a potentially promising target for certain types
of tumors [22].
In breast cancer, gene silencing p90RSK resulted in
decreased number of tumor initiating cell phenotype
represented by changes in surface marker such as CD44
and decreased ability to form mammosphere [23]. Ad-
ditionally, Xian et al. [24] have shown that treatment with
small molecules or small interfering RNA against p90RSK
can induce cell death in FGFR1-mediated transformed
cells. Our results showing the potential role of phospho-
p90RSK as a predictive marker of chemotherapy response
extend our understanding of the roles of p90RSK in breastcancer. Although a recent study suggested that the ef-
fect of p90RSK-induced cell proliferation can be modu-
lated independently of ERK activation, our results
show that the integrity of Ras/Raf/ERK and p90RSK
pathway is well-maintained in human breast cancer
tissues. Furthermore, gene silencing using siRNA
against p90RSK did not affect the cancer cells’ sensiti-
vity to doxorubicin suggesting the predictive role of
p90RSK is the result of Ras/Raf/ERK/p90RSK pathway
activity. Our results indicate that phospho-p90RSK can
be a useful marker for predicting chemotherapy
response but it may not be a suitable therapeutic target
for functional modulation.
While the relationship between ERK signaling pathway in
endocrine resistance is well-known in breast cancer [10],
the role of this pathway including p90RSK in modulating
chemotherapy response is yet to be explored. As mentioned
before, exposure to doxorubicin in breast cancer cell lines
resulted in phosphorylation of p90RSK which peaked
6 hours after the exposure [6]. Furthermore, MKP which
dephosphorylate ERK1/2 and p38 MAPK inhibit the
chemotherapy-induced JNK-related apoptotic pathway and
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[25] have shown that transient or stable overexpression of
MKP-1 reduced doxorubicin- or paclitaxel-induced apop-
tosis in MDA MB231 cells. However, there is also a contra-
dictory report showing the lack of association between Ras/
Raf/ERK pathway activation measured by immunohisto-
chemistry and clinical benefit from chemotherapy when
tumors of patients who participated in clinical trials were
analyzed [4]. Our results show that tumors with increased
phospho-p90RSK expression had 12% absolute benefit in
terms of proportional size reduction during the neoadju-
vant chemotherapy as measured by magnetic resonance
imaging. Indeed, increased ERK pathway signaling was
associated with enhanced apoptosis after anthracycline
treatment in a neuroblastoma cell line [26].
Interestingly, our results show that the association
between the chemotherapy response and the degree of
p90RSK phosphorylation is more evident in ER positive
tumors. Although the underlying mechanism is unknown,
it is possible to speculate that phospho-p90RSK can
increase the transcriptional activity of AF-1 of ER by phos-
phorylating Ser (167) [27]. In accordance with out results,
the phosphorylation of ER Ser(167) has been shown to be
correlated with phospho-p90RSK expression and was asso-
ciated with better treatment outcome in ER positive breast
cancer patients [28,29]. However, the relationship between
phospho-p90RSK and treatment outcome in breast cancer
should further be explored in a larger cohort of patients
since a recent study showed that the p90RSK mRNA level
was higher in triple negative breast cancer and was asso-
ciated with poor survival [23].
Our study carries some limitations. First we could not
eliminate the possibility of selection bias since our study is
a retrospective study including relatively small number of
patients who underwent neoadjuvant chemotherapy.
Second, the predictive role of phospho-p90RSK should be
independently addressed in patients who receive adjuvant
chemotherapy since the response to neoadjuvant chemo-
therapy and outcome after adjuvant chemotherapy may dif-
fer [30]. Especially, we could not find a statistically
significant relationship between phosphor-p90RSK expres-
sion and the incidence of pCR after neoadjuvant chemo-
therapy which is a well-known prognostic factor. Only a
borderline significance was seen in multivariate regression
analysis between phosphor-p90RSK and pCR. One possible
explanation would be that, in our data, the relationship
between the phosphor-p90RSK expression and chemothe-
rapy response was significant only in ER positive tumors.
ER positive tumors show significantly lower incidence of
pCR when compared to ER negative tumors and the both
tumors also differ in chemotherapy response patterns [31].
However, it is still important to predict chemotherapy-
responsiveness in terms of selecting patients who will
become candidates for successful breast conservationregardless of the likelihood of achieving pCR. Additionally,
we were not able to apply other pathologic response para-
meters such as residual cancer burden (RCB) index as pro-
posed by Symmans et al. [32]. Finally, the effector molecule
which modulates the relationship between the Ras/Raf/
ERK/p90RSK pathway activity and the chemotherapy sensi-
tivity should be investigated in future studies. Our data on
the association of phosphor-p90RSK and chemotherapy
sensitivity can be the results from different ERK activity
and proliferation activity in each cell lines.
Conclusion
In conclusion, by using human breast cancer samples
and cancer cell lines, we show that phospho-p90RSK
can be a potential marker for chemotherapy response in
ER positive breast cancer patients. The prognostic role
of phospho-p90RSK in breast cancer patients as well as
the functional mechanism underlying the association
between Ras/Raf/ERK/p90RSK pathway activity and
chemotherapy response should further be explored.
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Additional file 1: Figure S1. Scatter plot for the relationship between
phosphor-p90RSK expression and chemotherapy sensitivity in 12 breast
cancer cell lines. Cell survival denotes for the proportion of cancer cells
surviving after doxorubicin 10uM treatment. Pearson correlation
coefficient and p value were derived from correlation analysis.
Additional file 2: Table S1. Univariate and Multivariate analysis for
factors affecting pCR.
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